Multiple sclerosis
A combination of 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals, new research has found. The identified proteins could be used to tailor treatments to patients based on the expected severity of the disease. Julia Åkesson is doctoral student at Linköping University and the University of Skövde. The researcher [...]
An international project aimed at finding new treatments for progressive MS within the next 5 years has been announced. In progressive MS, mitochondria – the energy-producing powerhouses in cells including nerves – don’t function properly. This means nerves don’t get the energy they need and they die. The loss of these vulnerable nerves leads to permanent disability in progressive MS. A team involving the University of Edinburgh and researchers Cleveland, US will use mice to explore what happens to mitochondria and their energy production in nerve fibres and nerve cells in MS.
A six-month programme designed to help participants change their eating and lifestyle habits led to significant weight loss in people living with multiple sclerosis (MS) and obesity, new research revealed.
People who develop Multiple Sclerosis (MS) are more likely to have a number of underlying conditions years before their diagnosis, a new study reveals.
The injection of a type of stem cell into the brains of patients living with progressive multiple sclerosis (MS) has a long-lasting effect that appears to protect the brain from further damage, new research has found.
Multiple sclerosis (MS) patients with elevated levels of nerve biomarker NfL in their blood are at an increased risk of worsening disability within two years, new research led by UC San Francisco suggests.
NR Times reports on seven innovative projects changing the outlook for multiple sclerosis.
MS is a complex and unpredictable autoimmune disease of the central nervous system, affecting millions of people worldwide. The condition was previously deemed untreatable but over the last 20 years huge strides have been made in understanding MS, its causes and potential treatments. In recent months, ongoing efforts continue to deepen our comprehension of the condition, from EBV vaccine breakthroughs to the discovery of genetic variants responsible for speeding up MS progression.By Norman Putzki (MD PhD), global head development neuroscience and gene therapy at Novartis.
Over the last 30 years, remarkable progress has been made in the advancement of treating multiple sclerosis (MS), a potentially disabling disease that is most likely a consequence of complex autoimmune dysfunctions in the periphery ultimately leading to demyelination in the central nervous system (CNS).
Since 1993, a series of insights has led to greater understanding of the biological mechanisms and triggers driving the inflammatory attacks on the CNS.
These translational insights have also driven the development of newer and more effective treatments in MS.
Depression is unlikely to play a role in making disability progression worse in people with multiple sclerosis (MS), a new study published in Scientific Reports has found.
Researchers from Swansea University, University of Cambridge and Queen Mary University of London conducted the UK-wide study to find out if depression and/or anxiety put people with MS at greater risk of disability progression.
Body's fight against Epstein-Barr virus could cause or worsen Multiple Sclerosis, research reveals
